Direct-to-Consumer Advertising of Prescription Drugs: What Can the Swiss Experience Tell Policy-Makers in the United States?

Direct‑to‑consumer advertising (DTCA) of prescription drugs refers to the promotion of prescription‑only medicines directly to patients and the general public through channels such as television, print, and online media, and it remains a contested practice. In this editorial, we examine the tension between the purported benefits of DTCA (greater disease awareness and patient engagement) and its documented harms, including distorted expectations, brand-driven demand, and higher drug spending. Using Switzerland's more restrictive approach to public promotion and its integration of cost-effectiveness into reimbursement decisions as a contrasting model, we argue that recent United States enforcement actions should be a starting point for structural reform rather than isolated crackdowns. We propose tighter limits on DTCA for higher‑risk drugs, stronger standards for risk communication, and closer alignment of advertising privileges with clinical and economic value, alongside support for pharmacists who manage advertising-driven requests. These changes would better align pharmaceutical promotion with patient safety, rational prescribing, and health-system sustainability.